Epidemiologic review of the calcium channel blocker drugs

An up-to-date perspective on the proposed hazards

Jorge Kizer, Stephen E. Kimmel

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes, β-blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for β-blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.

Original languageEnglish (US)
Pages (from-to)1145-1158
Number of pages14
JournalArchives of Internal Medicine
Volume161
Issue number9
StatePublished - 2001
Externally publishedYes

Fingerprint

Calcium Channel Blockers
Dihydropyridines
Pharmaceutical Preparations
Ventricular Dysfunction
Safety
Stable Angina
Therapeutics
Acute Coronary Syndrome
Angiotensin-Converting Enzyme Inhibitors
Suicide
Clinical Trials
Hemorrhage
Hypertension
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Epidemiologic review of the calcium channel blocker drugs : An up-to-date perspective on the proposed hazards. / Kizer, Jorge; Kimmel, Stephen E.

In: Archives of Internal Medicine, Vol. 161, No. 9, 2001, p. 1145-1158.

Research output: Contribution to journalArticle

@article{fd734628e26c4b4b8dbc470fedb0f6eb,
title = "Epidemiologic review of the calcium channel blocker drugs: An up-to-date perspective on the proposed hazards",
abstract = "In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes, β-blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for β-blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.",
author = "Jorge Kizer and Kimmel, {Stephen E.}",
year = "2001",
language = "English (US)",
volume = "161",
pages = "1145--1158",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Epidemiologic review of the calcium channel blocker drugs

T2 - An up-to-date perspective on the proposed hazards

AU - Kizer, Jorge

AU - Kimmel, Stephen E.

PY - 2001

Y1 - 2001

N2 - In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes, β-blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for β-blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.

AB - In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes, β-blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for β-blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.

UR - http://www.scopus.com/inward/record.url?scp=0034927862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034927862&partnerID=8YFLogxK

M3 - Article

VL - 161

SP - 1145

EP - 1158

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 9

ER -